Heximar Ointment contains Calcipotriol 0.005% w/w, a synthetic derivative of vitamin D3 used primarily in the management of psoriasis vulgaris. Calcipotriol acts by modulating keratinocyte proliferation and differentiation, thereby reducing the hyperproliferative epidermal activity characteristic of psoriatic lesions. The ointment formulation facilitates topical application, allowing targeted treatment with minimal systemic absorption. Heximar Ointment is indicated for the treatment of stable plaque psoriasis affecting the scalp and body, providing symptomatic relief by reducing scaling, erythema, and plaque thickness. It is typically applied once or twice daily to the affected areas, avoiding contact with the eyes, mucous membranes, and open wounds. Treatment duration should be limited to the period recommended by a healthcare professional to minimize potential adverse effects. Common side effects may include local irritation, itching, or erythema at the application site, which are generally mild and transient. Caution is advised in patients with disorders of calcium metabolism or sensitivity to vitamin D analogues. Heximar Ointment should be used under medical supervision, especially in pediatric or pregnant patients. It is contraindicated in cases of hypersensitivity to Calcipotriol or any ointment excipients. Regular monitoring is recommended to assess treatment efficacy and tolerability.